small
Lv2
174 积分
2023-05-06 加入
-
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
1天前
待确认
-
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
1天前
已完结
-
A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma
2天前
已完结
-
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
2天前
已完结
-
The immune‐enhancing effect and in vitro antioxidant ability of different fractions separated from Colla corii asini
1个月前
已完结
-
Effects of Ejiao peptide–iron chelates on intestinal inflammation and gut microbiota in iron deficiency anemic mice
1个月前
已完结
-
[Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]
6个月前
已完结
-
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
7个月前
已完结
-
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study
7个月前
已完结
-
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
7个月前
已完结